• 1
    Soriano V, García-Samaniego J, Bravo R, Valencia E, Laguna F, de Pouplana M, et al. Morbidity and mortality associated with chronic viral hepatopathy in patients infected with the human immunodeficiency virus. Med Clin (Bar) 1995; 104: 641644.
  • 2
    Staples CT, Rimland D, Dudas D. Hepatitis C in the HIV (human immunodeficiency virus) Atlanta V.A. (Veterans Affairs Medical Center) Cohort Study (HAVACS): the effect of coinfection on survival. Clin Infect Dis 1999; 29: 150154.
  • 3
    Bica I, McGovern B, Dhar R, Stone D, McGowan K, Scheib R, et al. Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis 2001; 32: 492497.
  • 4
    Camino X, Iribarren JA, Arrizabalaga J, Rodríguez F, Von Wichmann AM. Causes of mortality among patients infected with the human immunodeficiency virus in the era of high active antiretroviral therapy. Enferm Infecc Microbiol Clin 2001; 19: 8586.
  • 5
    Manns MP, McHutchinson JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958965.
  • 6
    Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975982.
  • 7
    Rubin RH, Tolkoff-Rubin NE. The problem of human immunodeficiency virus (HIV) infection and transplantation. Transpl Int 1988; 1: 3642.
  • 8
    Policies & bylaws. Alexandria, Va.: United Network for Organ Sharing, 2001 ( = aboutpolicies).
  • 9
    Ragni MV, Dodson SF, Hunt SC, Bontempo FA, Fung JJ. Liver transplantation in haemophilia patients with acquired immunodeficiency syndrome. Blood 1999; 93: 11131114.
  • 10
    Gow PJ, Mutimer D. Liver transplantation for an HIV-positive patient in the era of high active antiretroviral therapy. AIDS 2001; 15: 291292.
  • 11
    Schliefer K, Paar W, Aydermir G, Wolff M, Rockstroh JK, Spengler U, et al. Orthotopic liver transplantation in a 33-year-old patient with fulminate hepatitis B and HIV infection. Dtsch Med Wochenschr 2000; 125: 523526.
  • 12
    Boyd AE, Taylor C, Norris S, Pozniak A, Prachalias A, Srinivasan P, et al. Liver Transplantation and HIV-a case series of 7 patients [Abstract 578]. In: Program and Abstracts of the 8th Conference on Retroviruses and Opportunistic Infections, Chicago, Illinois, 2001.
  • 13
    Vittecoq D, Teicher E, Merad M, Vallee JD, Dussaix E, Samuel D. Liver transplantation: is it possible in HIV / HCV co-infected patients? Pathol Biol 2003; 51: 525527.
  • 14
    Radecke K, Miller M, Ross B, Treichel U, Gerken G. Short term outcome in five HIV infected patients with terminal liver disease after orthotopic liver transplantation. Hepatology 2002; 36: 190.
  • 15
    Stock PG, Roland ME, Carlson L, Freise CE, Roberts JP, Hirose R, et al. Kidney and liver transplantation in human immunodeficiency virus-infected patients: a pilot safety and efficacy study. Transplantation 2003; 76: 370375.
  • 16
    Neff GW, Bonham A, Tzakis AG, Ragni M, Jayaweera D, Schiff ER, et al. Orthotopic liver transplantation in patients with human immunodeficiency virus and end-stage liver disease. Liver Transpl 2003; 9: 239247.
  • 17
    Ragni MV, Belle SH, Im K, Neff G, Roland M, Stock P, et al. Survival of human immunodeficiency virus-infected liver transplant recipients. J Infect Dis. 2003; 188: 14121420.
  • 18
    Ayats-Ardite J, Cisneros-Herreros JM, Pérez-Sáenz JL, Torre-Cisneros J. Infectious disease assessment in solid organ transplant candidates. Enferm Infecc Microbiol Clin 2002; 20: 448461.
  • 19
    Costigliola P, Tumietto F, Zagnoli A, Chiodo F, for Project HOST. Need for liver transplant in HIV-positive patients: first results of a specific survey in Italy, Project HOST. AIDS 2003; 17: 21192121.
  • 20
    Roland ME, Stock PG. Review of solid-organ transplantation in HIV-infected patients. Transplantation 2003; 75: 425429.
  • 21
    Roland ME, Bernard L, Braff J, Stock PG. Key clinical, ethical, and policy issues in the evaluation of the safety and effectiveness of solid organ transplantation in HIV-infected patients. Arch Intern Med 2003; 163: 17731778.
  • 22
    Jain AK, Venkataramanan R, Shapiro R, Scantlebury VP, Potdar S, Bonham CA, et al. The interaction between antiretroviral agents and tacrolimus in liver and kidney transplant patients. Liver Transpl 2002; 8: 841845.
  • 23
    Brinkman K, Huysmans F, Burger DM. Pharmacokinetic interaction between saquinavir and cyclosporine. Ann Intern Med 1998; 129: 914915.
  • 24
    Paterson DL, Singh N. Interactions between tacrolimus and antimicrobial agents. Clin Infect Dis 1997; 25: 14301440.
  • 25
    Jain AK, Venkataramanan R, Fridell JA, Gadomski M, Shaw LM, Ragni M, et al. Nelfinavir, a protease inhibitor, increases sirolimus levels in liver transplantation patient: a case report. Liver Transpl 2002; 8: 838840.
  • 26
    Tseng A, Nguyen ME, Cardella C, Humar A, Conly J. Probable interaction between efavirenz and cyclosporine. AIDS 2002; 16: 505506.
  • 27
    Gulick RM, Ribaudo HJ, Shijuma CM, Lustgarten S, Squires KE, Meyer WA III, et al. Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. N Engl J Med 2004; 350: 18501861.
  • 28
    Panel on Clinical Practices for Treatment of HIV convened by the Department of Health and Human Services (DHHS) and the Henry J. Kaiser Family Foundation. Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents, March 23, 2004.
  • 29
    Martínez E, Arnaiz JA, Podzamczer D, Dalmau D, Ribera E, Domingo P, et al. Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection. N Engl J Med 2003; 349: 10361046.
  • 30
    Jemsek J, Hutcherson J, Harper E. Poor virologic responses and early emergence of resistance in treatment naïve, HIV-infected patients receiving a once daily triple nucleoside regimen of didanosine, lamivudine, and tenofovir DF [Abstract 51]. In: Program and Abstracts of the 11th Conference on Retroviruses and Opportunistic Infections, San Francisco, California, 2004.
  • 31
    Gallant JE, Rodriguez AE, Weinberg W, et al. Early non-response to tenofovir DF (TDF) + abacavir (ABC) and lamivudine (3TC) in a randomized trial compared to efavirenz (EFV) + ABC and 3TC: ESS30009 unplanned interim analysis [Abstract H-1722a]. In: Program and Abstracts of the 43rd ICAAC, Chicago, Illinois, 2003.
  • 32
    Hoogewerf M, Regez RM, Schouten WE, Weigel HM, Frissen PH, Brinkman K. Change to abacavir-lamivudine-tenofovir combination treatment in patients with HIV-1 who had complete virological suppression. Lancet 2003; 13: 19791980.
  • 33
    Rufi G, Barcena R, Vargas V, Valdivieso A, Miró JM, Salcedo M, and The Spanish OLT-HIV Working Group. Orthotopic liver transplantation in 15 HIV-1-infected recipients: evaluation of Spanish experience in the HAART era (2002-2003) [Abstract 827]. In: 11th Conference on Retroviruses and Opportunistic Infections, San Francisco, California, February 8-11, 2004.
  • 34
    Tolan D, Davies MH, Millson CE. Fibrosing cholestatic hepatitis after liver transplantation in a patient with hepatitis C and HIV infection. N Eng J Med 2001; 345: 1781.
  • 35
    Bizollon T, Ducerf C, Trepo C, Multimer D. Hepatitis C virus recurrence after liver transplantation. Gut 1999; 44: 575578.
  • 36
    Samuel D, Feray C. Recurrent hepatitis C after liver transplantation: clinical and therapeutic issues. J Viral Hepat 2000; 7: 8792.
  • 37
    Taniguchi M, Shakil O, Vargas HE, Laskus T, Demetris AJ, Gayowski T, et al. Clinical and virologic outcomes of hepatitis B and C viral coinfection after liver transplantation: effect of viral hepatitis D. Liver Transpl 2000; 6: 9296.
  • 38
    Pontisso P, Ruvoletto MG, Fattovich G, Chemello L, Gallorini A, Ruol A, et al. Clinical and virological profiles in patients with multiple hepatitis virus infections. Gastroenterology 1993; 105: 15291533.